ark invest ai ramps up bets with CoreWeave stake and OpenAI entry

In a series of recent portfolio moves, Cathie Wood sharpened ARK Invest AI exposure while reshaping positions across genomics, logistics, and clean energy names.

CoreWeave stake marks major bet on AI infrastructure

The most consequential transaction centered on CoreWeave, an Nvidia-partnered cloud infrastructure provider focused on GPU-accelerated data centers for artificial intelligence workloads. Over three consecutive trading sessions on March 30, March 31, and April 1, ARK accumulated 83,764 CoreWeave shares, valued at approximately $6.9 million at the $82 closing price.

CoreWeave’s customer base includes technology heavyweights Google and Microsoft, underscoring its role in large-scale AI deployments. The company reported fourth-quarter revenue of $1.57 billion in February, a year-on-year surge of 110%. However, its first-quarter outlook of $1.9 to $2 billion lagged the $2.29 billion analyst consensus, tempering some market expectations.

Moreover, Bank of America upgraded CoreWeave to a buy rating in March and set a $100 price objective. The bank’s analysts emphasized the company’s positioning within an AI infrastructure market they estimate at $79 billion. CoreWeave shares settled at $82.24 on April 2 and have gained 15% year to date, reinforcing ARK’s thesis on scalable compute capacity.

First direct OpenAI stake across three ARK ETFs

In parallel, ARK established its inaugural direct position in OpenAI, the organization behind ChatGPT. Three ARK exchange-traded funds — ARKF, ARKK, and ARKW — collectively acquired 348,995 OpenAI shares or units through a Series C allocation. ARK described the transaction as its first direct cap table participation in OpenAI, signaling stronger conviction in foundational model providers.

This move complements ARK’s broader innovation mandate, which increasingly targets platforms that can monetize generative AI at scale. However, the stake also introduces private-market exposure into vehicles better known for listed, high-beta growth stocks.

Expansion into autonomous trucking and nuclear innovation

Beyond software and cloud infrastructure, ARK broadened its reach into physical-world AI applications. The ARKQ fund purchased 230,000 shares of Kodiak AI, which focuses on autonomous trucking systems and AI-driven logistics solutions. The position underscores ARK Invest AI conviction in self-driving freight as a long-term efficiency driver for supply chains.

Moreover, ARK secured approximately 56,000 shares of Oklo, an advanced nuclear energy company developing next-generation fission reactor technology. The investment aligns with ARK’s thesis that abundant, low-carbon power will be critical to support increasingly compute-intensive AI workloads.

DoorDash also joined ARK’s portfolio as the manager expanded exposure to consumer technology platforms. The meal delivery company offers potential operating leverage from AI-enhanced logistics and demand forecasting, though competition and regulatory scrutiny remain key risks.

Genomics allocations through ARKG and ARKK

Within healthcare innovation, ARK increased positions in several genomics-related names. The ARKG fund acquired more than 16,000 shares of Arcturus Therapeutics, a developer of RNA-based therapeutics targeting infectious diseases and other indications. That said, RNA modalities remain an emerging field, with clinical and regulatory execution crucial to long-term value.

Additionally, ARK bought 39,000 shares of GeneDx, a precision medicine and genetic diagnostics company. The shares were split between ARKG and ARKK, reinforcing Wood’s view that genomic sequencing and data analytics can unlock new diagnostic and treatment paradigms.

Portfolio reductions and strategic exits

While adding to high-conviction innovation themes, ARK also trimmed or exited several holdings. The largest sale by volume involved Strata Critical Medical, where ARK liquidated 745,000 shares worth roughly $3 million. The move suggests a reallocation of capital from legacy health positions into higher-growth AI and genomics targets.

Furthermore, ARK cut its stake in Veracyte, a molecular diagnostics firm, and reduced exposure to semiconductor testing specialist Teradyne. Social platform Pinterest, media and entertainment company Discovery, and Japanese digital services group LY Corp also saw position reductions as ARK rebalanced toward its highest-conviction disruptors.

Performance pressures and Wood’s AI acceleration thesis

These portfolio changes arrive as flagship fund ARKK faces sustained performance and flow headwinds. The ETF has declined approximately 12% year to date, compared with a 3.8% drop for the S&P 500. Over the past 12 months, ARKK has recorded about $1.2 billion in net investor redemptions, highlighting investor sensitivity to volatility in high-growth names.

However, Cathie Wood continues to articulate a bullish long-term view on artificial intelligence as a macroeconomic catalyst. She expects a “great acceleration” in global growth driven by AI adoption. According to her projections, AI training expenses are falling roughly 75% annually, while inference costs are dropping between 85% and 98% per year, potentially expanding margins across data-intensive industries.

In this context, ARK Invest AI repositioning around infrastructure, foundational models, autonomous logistics, genomics, and nuclear energy underscores a bet that the next decade of equity returns will be led by platforms monetizing exponential cost declines in computing and data. The firm is effectively trading near-term volatility for longer-duration optionality in transformative technologies.

Overall, ARK’s latest trades show a deliberate rotation toward AI-aligned infrastructure, frontier genomics, and clean energy, even as flagship ETF performance and outflows pressure the strategy, confirming Wood’s commitment to concentrated, high-conviction innovation themes.